Abstract
Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Current Pharmaceutical Design
Title:Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Volume: 20 Issue: 12
Author(s): Evangelos P. Daskalopoulos, Kevin C.M. Hermans and W. Matthijs Blankesteijn
Affiliation:
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Abstract: Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Export Options
About this article
Cite this article as:
Daskalopoulos P. Evangelos, Hermans C.M. Kevin and Blankesteijn Matthijs W., Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990452
DOI https://dx.doi.org/10.2174/13816128113199990452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Biology of Mesenchymal Stem Cells
Current Rheumatology Reviews Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions
Current Pediatric Reviews Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets MRI of Pancreas in Patients with Chronic Pancreatitis and Healthy Volunteers: Can Pancreatic Signal Intensity and Contrast Enhancement Patterns be Valuable Predictors of Early Chronic Pancreatitis?
Current Medical Imaging Diabetes Beyond Insulin: Review of New Drugs for Treatment of Diabetes Mellitus
Current Drug Discovery Technologies The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Tumor Growth is Stimulated by Muscarinic Receptor Agonism: Role of Autoantibodies in Breast Cancer Patients
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chirality of Central Nervous System (CNS) Acting Drugs: A Formidable Therapeutic Hurdle Against CNS Diseases
Central Nervous System Agents in Medicinal Chemistry The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Vascular effects of flavonoids
Current Medicinal Chemistry Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals